Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29952705.
- Also identified by DOI 10.18553/jmcp.2018.24.7.711 and PMC identifier 10397654.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ailawadhi reports research support from Pharmacyclics and consulting relationships with Takeda, Amgen, and Celgene. Jakubowiak reports consulting and advisory board relationships with AbbVie, Amgen, BMS, Celgene, Karyopharm, SkylineDX, and Takeda. Panjabi, Campioni, and Majer are employees of and stockholders in Amgen.
Medical subject headings
- Multiple Myeloma